IS7268A - Chemically altered synthetic human growth hormone - Google Patents
Chemically altered synthetic human growth hormoneInfo
- Publication number
- IS7268A IS7268A IS7268A IS7268A IS7268A IS 7268 A IS7268 A IS 7268A IS 7268 A IS7268 A IS 7268A IS 7268 A IS7268 A IS 7268A IS 7268 A IS7268 A IS 7268A
- Authority
- IS
- Iceland
- Prior art keywords
- growth hormone
- human growth
- chemically altered
- synthetic human
- altered synthetic
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title 1
- 108010000521 Human Growth Hormone Proteins 0.000 title 1
- 239000000854 Human Growth Hormone Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33190701P | 2001-11-20 | 2001-11-20 | |
| PCT/US2002/037270 WO2003044056A2 (en) | 2001-11-20 | 2002-11-20 | Chemically-modified human growth hormone conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7268A true IS7268A (en) | 2004-05-17 |
Family
ID=23295870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7268A IS7268A (en) | 2001-11-20 | 2004-05-17 | Chemically altered synthetic human growth hormone |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1453859A2 (en) |
| JP (2) | JP2005525302A (en) |
| KR (2) | KR20050044858A (en) |
| CN (1) | CN1608079A (en) |
| AP (1) | AP2004003050A0 (en) |
| AU (1) | AU2002356990A1 (en) |
| BR (1) | BR0214451A (en) |
| CA (1) | CA2467731A1 (en) |
| CO (1) | CO5580794A2 (en) |
| EA (2) | EA008505B1 (en) |
| EC (1) | ECSP045114A (en) |
| GE (1) | GEP20063860B (en) |
| HR (1) | HRP20040448A2 (en) |
| HU (1) | HUP0500997A2 (en) |
| IL (1) | IL162031A0 (en) |
| IS (1) | IS7268A (en) |
| MA (1) | MA27544A1 (en) |
| MX (1) | MXPA04004809A (en) |
| NO (1) | NO20042182L (en) |
| OA (1) | OA13063A (en) |
| PL (1) | PL374354A1 (en) |
| RS (1) | RS53104A (en) |
| TN (1) | TNSN04090A1 (en) |
| WO (1) | WO2003044056A2 (en) |
| ZA (1) | ZA200403907B (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| US7041855B2 (en) | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| WO2003049699A2 (en) * | 2001-12-11 | 2003-06-19 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
| US6956135B2 (en) | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| DK1476181T3 (en) * | 2002-01-18 | 2016-05-23 | Biogen Ma Inc | POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF |
| MXPA05002620A (en) | 2002-09-09 | 2005-05-05 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals. |
| EP1591467A1 (en) * | 2002-09-09 | 2005-11-02 | Nektar Therapeutics Al, Corporation | Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone |
| US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| US20050281778A1 (en) * | 2003-03-28 | 2005-12-22 | Myung-Ok Park | Human growth hormone conjugated with biocompatible polymer |
| EP1673464A2 (en) * | 2003-10-10 | 2006-06-28 | Novo Nordisk A/S | Conjugation of peptides |
| US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| EP2368579A1 (en) * | 2004-01-21 | 2011-09-28 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| JP2008511610A (en) * | 2004-08-31 | 2008-04-17 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Glycerol-branched polyethylene glycol-human growth hormone conjugates, methods for their production and use |
| MX2007007590A (en) | 2004-12-22 | 2007-12-10 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides. |
| US8080391B2 (en) * | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
| EP2284191A3 (en) * | 2004-12-22 | 2011-07-20 | Ambrx, Inc. | Process for the preparation of hGH |
| JP2008531482A (en) | 2005-02-10 | 2008-08-14 | ノボ ノルディスク アクティーゼルスカブ | Growth hormone with PEGylated C-terminus |
| BRPI0609079A2 (en) | 2005-04-18 | 2010-11-16 | Novo Nordisk As | peptide, pharmaceutical composition, method for the treatment of cancer, use of a peptide nucleic acid construct, vector, host, and, antibody |
| WO2007025988A2 (en) | 2005-08-30 | 2007-03-08 | Novo Nordisk Health Care Ag | Liquid formulations of pegylated growth hormone |
| HRP20110404T1 (en) * | 2005-11-08 | 2011-08-31 | Ambrx | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
| ES2529065T3 (en) * | 2005-12-14 | 2015-02-16 | Ambrx, Inc. | Compositions they contain, procedures that involve and uses of unnatural amino acids and polypeptides |
| US9175061B2 (en) * | 2006-07-07 | 2015-11-03 | Novo Nordisk Health Care Ag | Protein conjugates and methods for their preparation |
| CN101108895B (en) * | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | Polyglycol ethanal derivant and combo of medicament and the same |
| CN101553501A (en) | 2006-10-26 | 2009-10-07 | 诺沃-诺迪斯克有限公司 | IL-21 variants |
| CL2008002399A1 (en) * | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c. |
| BRPI0822530B1 (en) * | 2008-04-03 | 2022-03-22 | Biosteed Gene Expression Tech. Co., Ltd | Method of preparing a polyethylene glycolated human growth hormone (peg-modified), peg-modified human growth hormone of lower apparent molecular weight and its use, preparation of peg-modified human growth hormone of lower apparent molecular weight and its method of preparation and composition |
| DK2279007T3 (en) | 2008-04-29 | 2016-08-22 | Ascendis Pharma Growth Disorders Div As | Pegylated recombinant relations of human growth hormone |
| KR101104574B1 (en) * | 2008-05-14 | 2012-01-11 | 성균관대학교산학협력단 | Human Growth Hormone Chemically Modified with Polyethylene Glycol, Method of Preparation and Use thereof |
| CN102131844B (en) * | 2008-07-31 | 2016-03-02 | 药华医药股份有限公司 | Peptide-polymer conjugates |
| MX2011000847A (en) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Conjugated proteins with prolonged in vivo efficacy. |
| RU2409669C9 (en) * | 2008-08-18 | 2012-05-27 | ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") | Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods |
| EP2331139B1 (en) * | 2008-09-11 | 2019-04-17 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
| MX2011007736A (en) | 2009-01-22 | 2011-09-06 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds. |
| WO2011015649A1 (en) | 2009-08-06 | 2011-02-10 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
| DK2512450T3 (en) | 2009-12-15 | 2018-04-23 | Ascendis Pharma Endocrinology Div A/S | Dry growth hormone composition transiently bound to a polymer carrier |
| CN118767117A (en) | 2010-01-22 | 2024-10-15 | 诺沃—诺迪斯克保健股份有限公司 | Growth hormone with prolonged effect in vivo |
| BR112012018162A2 (en) | 2010-01-22 | 2017-10-03 | Novo Nordisk Healthcare Ag | STABLE GROWTH HORMONE COMPOUNDS |
| CA2798518A1 (en) * | 2010-05-17 | 2011-11-24 | Cebix, Inc. | Pegylated c-peptide |
| EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
| EA019967B1 (en) * | 2011-12-21 | 2014-07-30 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Polyethyleneglycol covalent conjugate with human growth hormone |
| CN105120887A (en) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | Growth hormone compound formulation |
| US11559567B2 (en) | 2014-11-06 | 2023-01-24 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
| US10799563B2 (en) | 2014-11-18 | 2020-10-13 | Ascendis Pharma Endocrinology Division | Polymeric hGH prodrugs |
| PL3220892T3 (en) | 2014-11-21 | 2022-01-31 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
| KR20170125839A (en) * | 2015-03-11 | 2017-11-15 | 넥타르 테라퓨틱스 | Conjugates of an il-7 moiety and an polymer |
| KR102152437B1 (en) * | 2015-09-18 | 2020-09-07 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | Long acting adrenomedulin derivatives |
| SG11202108735QA (en) | 2019-03-04 | 2021-09-29 | Ascendis Pharma Endocrinology Div A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
| CN114539384B (en) * | 2020-11-19 | 2024-09-06 | 江苏众红生物工程创药研究院有限公司 | Pegylated long-acting growth hormone, preparation method and medical application thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| ES2113354T3 (en) * | 1990-05-04 | 1998-05-01 | American Cyanamid Co | STABILIZATION OF SOMATOTROPINS AND OTHER PROTEINS BY MODIFICATION OF CYSTEINE WASTE. |
| JPH06506217A (en) * | 1991-03-18 | 1994-07-14 | エンゾン，インコーポレーテッド | Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers |
| AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| JP3628333B2 (en) * | 1995-09-21 | 2005-03-09 | ジェネンテック インコーポレーテッド | Human growth hormone mutant |
| IL133974A0 (en) * | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
| ATE526401T1 (en) * | 1999-01-14 | 2011-10-15 | Bolder Biotechnology Inc | METHOD FOR PRODUCING PROTEINS WITH FREE CYSTEINE RESIDUE |
| IL144361A0 (en) * | 1999-01-29 | 2002-05-23 | Hoffmann La Roche | Gcsf conjugates |
| WO2001076639A2 (en) * | 2000-04-06 | 2001-10-18 | Pharmacia Corporation | Chemically-modified myelopoietin conjugates |
| WO2002055532A2 (en) * | 2001-01-11 | 2002-07-18 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
-
2002
- 2002-11-20 HR HR20040448A patent/HRP20040448A2/en not_active Application Discontinuation
- 2002-11-20 CA CA002467731A patent/CA2467731A1/en not_active Abandoned
- 2002-11-20 OA OA1200400143A patent/OA13063A/en unknown
- 2002-11-20 KR KR1020047007708A patent/KR20050044858A/en not_active Abandoned
- 2002-11-20 EA EA200400565A patent/EA008505B1/en unknown
- 2002-11-20 IL IL16203102A patent/IL162031A0/en unknown
- 2002-11-20 EA EA200700431A patent/EA200700431A1/en unknown
- 2002-11-20 CN CNA028259289A patent/CN1608079A/en active Pending
- 2002-11-20 AU AU2002356990A patent/AU2002356990A1/en not_active Abandoned
- 2002-11-20 WO PCT/US2002/037270 patent/WO2003044056A2/en not_active Ceased
- 2002-11-20 RS YU53104A patent/RS53104A/en unknown
- 2002-11-20 EP EP02803695A patent/EP1453859A2/en not_active Withdrawn
- 2002-11-20 HU HU0500997A patent/HUP0500997A2/en unknown
- 2002-11-20 BR BRPI0214451-4A patent/BR0214451A/en not_active IP Right Cessation
- 2002-11-20 KR KR1020077011730A patent/KR20070072924A/en not_active Withdrawn
- 2002-11-20 AP APAP/P/2004/003050A patent/AP2004003050A0/en unknown
- 2002-11-20 PL PL02374354A patent/PL374354A1/en unknown
- 2002-11-20 GE GE5599A patent/GEP20063860B/en unknown
- 2002-11-20 MX MXPA04004809A patent/MXPA04004809A/en not_active Application Discontinuation
- 2002-11-20 JP JP2003545691A patent/JP2005525302A/en active Pending
-
2004
- 2004-05-17 IS IS7268A patent/IS7268A/en unknown
- 2004-05-19 MA MA27686A patent/MA27544A1/en unknown
- 2004-05-20 EC EC2004005114A patent/ECSP045114A/en unknown
- 2004-05-20 ZA ZA200403907A patent/ZA200403907B/en unknown
- 2004-05-20 CO CO04046633A patent/CO5580794A2/en not_active Application Discontinuation
- 2004-05-20 TN TNP2004000090A patent/TNSN04090A1/en unknown
- 2004-05-26 NO NO20042182A patent/NO20042182L/en not_active Application Discontinuation
-
2006
- 2006-07-14 JP JP2006193577A patent/JP2006321808A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA27544A1 (en) | 2005-10-03 |
| HRP20040448A2 (en) | 2006-02-28 |
| JP2005525302A (en) | 2005-08-25 |
| NO20042182L (en) | 2004-08-11 |
| KR20070072924A (en) | 2007-07-06 |
| GEP20063860B (en) | 2006-06-26 |
| EP1453859A2 (en) | 2004-09-08 |
| WO2003044056A2 (en) | 2003-05-30 |
| RS53104A (en) | 2006-10-27 |
| TNSN04090A1 (en) | 2006-06-01 |
| ECSP045114A (en) | 2004-07-23 |
| PL374354A1 (en) | 2005-10-17 |
| KR20050044858A (en) | 2005-05-13 |
| EA200700431A1 (en) | 2008-02-28 |
| ZA200403907B (en) | 2007-12-27 |
| CA2467731A1 (en) | 2003-05-30 |
| IL162031A0 (en) | 2005-11-20 |
| MXPA04004809A (en) | 2004-08-11 |
| EA200400565A1 (en) | 2005-06-30 |
| CN1608079A (en) | 2005-04-20 |
| WO2003044056A3 (en) | 2003-08-21 |
| JP2006321808A (en) | 2006-11-30 |
| HUP0500997A2 (en) | 2007-11-28 |
| CO5580794A2 (en) | 2005-11-30 |
| AP2004003050A0 (en) | 2004-06-30 |
| BR0214451A (en) | 2006-05-30 |
| EA008505B1 (en) | 2007-06-29 |
| AU2002356990A1 (en) | 2003-06-10 |
| OA13063A (en) | 2006-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7268A (en) | Chemically altered synthetic human growth hormone | |
| DK1524272T3 (en) | growth hormone | |
| AU2002342653A8 (en) | Modified growth hormone | |
| DE60108654D1 (en) | HARVESTER | |
| DE50210654D1 (en) | Harvester | |
| DK1440077T3 (en) | SYNTHETIC HEPARINPENTASACCHARIDES | |
| ATE392508T1 (en) | ARTIFICIAL GRASS | |
| FI20010694L (en) | Implant | |
| DE50209261D1 (en) | mowing | |
| NO20024890D0 (en) | implant | |
| DK1542716T3 (en) | Growth hormone releasing peptides | |
| FR2815535B1 (en) | PEDICULAR IMPLANT | |
| DK1333853T3 (en) | Growth Factor Complex | |
| DE60238111D1 (en) | VISZERALFETTMESSER WITH TONOMETER | |
| EP1401431A4 (en) | HUMAN GROWTH HORMONE ANTAGONISTS | |
| DE50209070D1 (en) | seeder | |
| FR2810231B1 (en) | SYNTHETIC CORNEA | |
| DE60232967D1 (en) | OKULAR TISSUE GROWTH FACTOR-SIMILAR PROTEIN | |
| FR2806309B1 (en) | IMPLANT | |
| DE60226191D1 (en) | Harvester | |
| HUP0402334A3 (en) | Modified human growth hormone | |
| FR2825281B1 (en) | DRAIN AND ITS APPLICATOR | |
| DE60200268D1 (en) | single crystal growth | |
| IS5999A (en) | Bone growth factor | |
| FR2825911B1 (en) | COTYLOIDIAN IMPLANT |